Jaka jest cena za Solasia Pharma K.K. (4597)

Cena za Solasia Pharma K.K. (4597) wynosi $0.20877985

Jaka jest kapitalizacja rynkowa dla Solasia Pharma K.K. (4597)

Kapitalizacja rynkowa dla Solasia Pharma K.K. (4597) wynosi $57.00M

Solasia Pharma K.K. (4597) Podziały Akcji

Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.

Rok	Podział	Mnożnik	Skumulowany mnożnik
Za mało danych dla podanych dat.

Rok

Podział

Mnożnik

Skumulowany mnożnik

Za mało danych dla podanych dat.

Firma	Liczba podziałów akcji	Skumulowany mnożnik	Kraj
MERCK Kommanditgesellschaft auf Aktien MER.SW	0	-	DE
Merck KGaA MRK.DE	0	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0	-	JP
Galderma Group AG GALD.SW	0	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5	x119	IN

Firma

Liczba podziałów akcji

Skumulowany mnożnik

Kraj